These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 19282568)

  • 21. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
    Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
    J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
    Meattini I; Livi L; Saieva C; Franceschini D; Scotti V; Mangoni M; Loi M; Di Brina L; Zei G; Bonomo P; Greto D; Gelain E; Nori J; Sanchez LJ; Orzalesi L; Bianchi S; Biti G
    Clin Breast Cancer; 2013 Aug; 13(4):247-53. PubMed ID: 23684167
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer.
    Yazilitas D; Sendur MA; Karaca H; Ozdemir N; Aksoy S; Berk V; Yazici O; Ozturk B; Ozkan M; Zengin N; Altundag K
    Asian Pac J Cancer Prev; 2015; 16(4):1471-7. PubMed ID: 25743817
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy.
    Miller M; Ottesen RA; Niland JC; Kruper L; Chen SL; Vito C
    Ann Surg Oncol; 2014 Oct; 21(10):3317-23. PubMed ID: 25059788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reconsideration of clinical and histopathological prognostic factors in breast cancer patients: a single center experience.
    Tanriverdi O; Meydan N; Barutca S
    Asian Pac J Cancer Prev; 2014; 15(2):807-12. PubMed ID: 24568500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breast Cancer in Men: a Report from the Department of Radiation Oncology in Kermanshah Province, Iran.
    Amirifard N; Sadeghi E
    Asian Pac J Cancer Prev; 2016; 17(5):2593-6. PubMed ID: 27268636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients with HER2-positive early breast cancer receiving adjuvant trastuzumab: clinicopathological features, efficacy, and factors affecting survival.
    Ulas A; Kos T; Avci N; Cubukcu E; Olmez OF; Bulut N; Degirmenci M
    Asian Pac J Cancer Prev; 2015; 16(4):1643-9. PubMed ID: 25743846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma.
    Nakopoulou L; Mylona E; Papadaki I; Kapranou A; Giannopoulou I; Markaki S; Keramopoulos A
    Pathobiology; 2005; 72(5):241-9. PubMed ID: 16374068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?
    Aurilio G; Bagnardi V; Graffeo R; Nolè F; Petit JY; Locatelli M; Martella S; Iera M; Rey P; Curigliano G; Rotmensz N; Munzone E; Goldhirsch A
    Anticancer Res; 2014 Nov; 34(11):6677-83. PubMed ID: 25368274
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Location of Receipt of Initial Treatment and Outcomes in Long-Term Breast Cancer Survivors.
    Sinha AK; Patel JR; Shen Y; Ueno NT; Giordano SH; Tripathy D; Lopez DS; Barcenas CH
    PLoS One; 2017; 12(1):e0170081. PubMed ID: 28085940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The prognostic significance of the insulin-like growth factor-1 ligand and receptor expression in breast cancer tissue.
    Chong KY; Subramanian A; Mokbel K; Sharma AK
    J Surg Oncol; 2011 Sep; 104(3):228-35. PubMed ID: 21480260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomised trial: One cycle of anthracycline-containing adjuvant chemotherapy compared with six cycles of CMF treatment in node-positive, hormone receptor-negative breast cancer patients.
    Ploner F; Jakesz R; Hausmaninger H; Kolb R; Stierer M; Fridrik M; Steindorfer P; Gnant M; Haider K; Mlineritsch B; Tschurtschenthaler G; Steger G; Seifert M; Kubista E; Samonigg H;
    Onkologie; 2003 Apr; 26(2):115-9. PubMed ID: 12771518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
    Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
    Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of prognostic effect of Cox-2 expression in primary breast cancer on short-term follow-up.
    Kelly LM; Hill AD; Kennedy S; Connolly EM; Ramanath R; Teh S; Dijkstra B; Purcell R; McDermott EW; O'Higgins N
    Eur J Surg Oncol; 2003 Nov; 29(9):707-10. PubMed ID: 14602487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.